argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
644.48
-3.01 (-0.46%)
Feb 21, 2025, 4:00 PM EST - Market closed
argenx SE Employees
argenx SE had 1,148 employees as of December 31, 2023. The number of employees increased by 305 or 36.18% compared to the previous year.
Employees
1,148
Change (1Y)
305
Growth (1Y)
36.18%
Revenue / Employee
$1,662,595
Profits / Employee
-$35,098
Market Cap
39.32B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,148 | 305 | 36.18% |
Dec 31, 2022 | 843 | 193 | 29.69% |
Dec 31, 2021 | 650 | 314 | 93.45% |
Dec 31, 2020 | 336 | 148 | 78.72% |
Dec 31, 2019 | 188 | 83 | 79.05% |
Dec 31, 2018 | 105 | 32 | 43.84% |
Dec 31, 2017 | 73 | 15 | 25.86% |
Dec 31, 2016 | 58 | 17 | 41.46% |
Dec 31, 2015 | 41 | 9 | 28.13% |
Dec 31, 2014 | 32 | 10 | 45.45% |
Dec 31, 2013 | 22 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
ARGX News
- 2 days ago - argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025 - GlobeNewsWire
- 5 weeks ago - argenx Highlights 2025 Strategic Priorities - GlobeNewsWire
- 6 weeks ago - argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewsWire
- 3 months ago - argenx to Present at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies - GlobeNewsWire
- 3 months ago - Steritas Announces Collaboration with argenx to Advance Evidence for Novel Steroid-sparing Therapeutics - Business Wire
- 3 months ago - argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China - GlobeNewsWire